Monday, August 25, 2008
Mesothelioma Survival Rates Among Patients Taking New Treatment
LegalView Recounts the Results of a Recent Mesothelioma Study That Reported High Survival Rates Among Patients Taking New Treatment
LegalView reported the results of an Italian study to its mesothelioma blog readers; the results detailed a positive outcome and increased survival rate for elderly pleural mesothelioma victims. The study, recently published in a British medical journal, used a combination of two medicinal treatments commonly prescribed separately.
Denver, CO, August 16, 2008 -- LegalView, the most comprehensive legal resource available on the Web, recounted the results of an Italian study to its mesothelioma information blog readers. The study attempted to increase the survival rate of elderly pleural mesothelioma patients by combining two medications: Alimta (pemtrexed) and Paraplatin (carboplatin). The results of the study were released in a June issue of the British Journal of Cancer and the conclusions detailed the highly-effective treatments, which increased the survival rate among pleural mesothelioma patients 65 years of age or older.
Mesothelioma is an incurable cancer that is often attributed to the inhalation of asbestos fibers and dust containing tremolite. Asbestos is a known carcinogen, according to the Environmental Protection Agency (EPA), which is responsible for regulating the cleanup of the hazardous material. Asbestos was often prized for its ability to remain fire-resistant, while being produced cheaply, and served as a key ingredient in many products including insulation that was implemented into homes, apartment complexes, universities, schools, business offices and hospitals around the country. Individuals who suffer from mesothelioma cancer are advised to speak with a knowledgeable mesothelioma attorney in order to better educate themselves on the possibility for developing a mesothelioma lawsuit. Due to the extremely costly medical bills associated with increasing survival rate among mesothelioma cancer victims, developing litigation may result in monetary compensation to assist with those medical bills.
LegalView not only offers resources on the most recent mesothelioma news and clinical trials, but also offers information on a variety of other legal issues afflicting millions of Americans. Most recently, LegalView updated several of its pharmaceutical drug information portals with news on updates and recalls; some of the portals include Viapro, Ketek and the Zimmer Durom cup.
The development of the Viapro information portal occurred after the U.S. Food and Drug Administration (FDA) issued a press release on the recall of the drug because of contamination of a harmful chemical known as thiomethisosildenafil. The male sexual-enhancement prescription drug, manufactured by EG Labs, is used to treat erectile dysfunction (ED). The undeclared ingredient may be harmful to patients especially when interacting with nitrates found in other prescription drugs. The Viapro recall occurred because the drug may cause dangerously low levels of blood pressure among patients also taking nitroglycerin for diabetes, high blood pressure, high cholesterol or heart disease.
Ketek, which is an antibiotic used to treat upper respiratory infections such as pneumonia, bronchitis and sinusitis, had its warning labels increased recently due to the threat of liver disease among patients consuming the drug. To learn more about the Ketek side effects, visit http://ketek.legalview.com/.
Also among the recently updated information portals is that of the Zimmer Durom cup. Zimmer Holdings has ceased production of its Durom cup because of complaints that the hip socket was failing among many patients. Although the company has ceased production of the hip socket, pending internal investigations into the potential failure, the hip socket has already been used in over 12,000 hip replacement procedures since its introduction to the market in 2006. Patients who may be at risk for the Durom cup failure should seek medical attention immediately to ensure no further damage occurs.
About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.
Contact Information
LegalView
Katie Kelley
720-771-3246
press-releases@legalview.com
www.legalview.com
Tuesday, August 19, 2008
Industry Makes Request to Decrease Asbestos Regulations
LegalView Offers Mesothelioma Blog Readers Details of Disconcerting Request to Decrease Asbestos Regulations from Industry
LegalView informed mesothelioma blog readers of an potentially troubling request by automotive, chemical and mining industries' paid researchers to "water down" asbestos regulations. The industry-hired scientists argued that asbestos is no longer as dangerous, even though several international health organizations have declared no safe level of the material.
Denver, CO - August 2, 2008 -- LegalView, the number one resource for everything and anything legal on the Internet, recently updated readers with the latest piece of mesothelioma information, relating to the request by paid researchers for the automotive, chemical and mining industries to decrease asbestos regulations. In a July 2008 summit in Washington D.C., the Environmental Protection Agency (EPA) met with the Office of Solid Waste and Emergency regarding the request. The industry researchers argued that asbestos fibers found in sand, taconite and other materials are less toxic than originally deemed in the 1980s when the regulations were created. However, the EPA along with the International Agency for Research on Cancer, the Occupational Safety and Health Administration (OSHA) and The World Health Organization (WHO) have all determined that no level of exposure to asbestos fibers is safe and the material as well as products using asbestos should be permanently banned.
Asbestos was mined for years and was frequently used in the construction industry for an array of products, most often insulation. However, it was determined that exposure to asbestos fibers causes a deadly form of lung cancer known as mesothelioma. Individuals who suffer from mesothelioma cancer should contact an experienced mesothelioma attorney to receive a legal consultation on the possibility of developing a personalized mesothelioma lawsuit. Because the cancer is fatal and no completely effective mesothelioma treatment exists to reduce the disease it may be important to develop litigation and potentially receive monetary compensation to pay for costly medical bills. Mesothelioma is a dormant condition that can take decades before symptoms reveal themselves, at which point, little can be done to improve the illness.
According to news reports, at the Washington D.C. summit, approximately 83 public health officials signed a 29-page report on the "science-for-hire" practice, which Dr. Michael Silverstein, who wrote the report, alleges is occurring on the part of automotive, chemical and mining industries. The report, opposing the request, urged the EPA to focus on public health rather than big industry and to avoid decreasing the asbestos regulations.
Learn more about this ongoing issue as well as other legal issues through LegalView.com. LegalView continues to maintain a comprehensive library of legal issues; issues that may be causing harm to millions of Americans each year. LegalView recently updated several of its issues to include detailed information and news. Some of the recently updated sites include information on the Zimmer Durom cup, the Ketek antibiotic and Avandia prescriptions.
The Durom cup, manufactured by Zimmer Holdings, is an artificial hip component that has been under fire by physicians who have said the device is failing their patients. Because of the alleged Zimmer Durom cup risks, the company has ceased manufacture of the hip socket. However, since production began in 2006, nearly 12,000 patients received the cup and may be affected by the failing hip socket and should contact a knowledgeable attorney for advice about the potential Durom cup recall.
Ketek is a pharmaceutical prescription antibiotic that is used to treat upper respiratory infections including pneumonia or bronchitis. Reports have tied the antibiotic with the possibility of severe liver damage among patients. Additional Ketek side effects may also be considered dangerous and those who report signs of yellowing skin or jaundice should consult a doctor immediately
The Avandia portal is continually being updated to provide the public with extensive research, scientific findings and experienced attorney links. Avandia is a prescription drug used to treat type 2 diabetes, which currently affects millions of individuals in the United States. Recent research, however, has found a disturbing link between the use of Avandia and an increase of heart disease as well as osteoporosis among patients. Individuals who feel they may have symptoms relating to heart disease or who have suffered from a bone fracture likely induced by the Avandia side effects, should speak with a medical expert immediately. Additionally, it is advisable to locate an experienced pharmaceutical law firm in case legal advice is necessary for an Avandia settlement.
About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.
CONTACT INFORMATION
Katie Kelley
LegalView
720-226-6613
Alan Haburchak
LegalView
720-226-6613
Tuesday, August 12, 2008
Revolutionary HIV Testing Bill Passes
Bill to 'Revolutionize' HIV Testing Passes California Legislature Unanimously
AB 2899 (Portantino, D-Pasadena), Sponsored by AIDS Healthcare Foundation (AHF), Overhauls Counseling Model for HIV Testing Programs; Bill Eliminates Outdated 'One Size Fits All' Approach for More Prudent Public Health Approach
SACRAMENTO, Calif.-- August 12, 2008 --AIDS Healthcare Foundation (AHF), the operator of the largest non-government HIV testing program in California, today praised the California Legislature for its passage this week of Assembly Bill 2899 (Portantino, D-Pasadena).
"AB 2899 will revolutionize the way we do HIV testing in California, and we strongly urge the Governor to sign this bill," said Michael Weinstein, President of AIDS Healthcare Foundation. "Today, in government-funded programs, extensive education and counseling is required for every person regardless of how many times they might have been tested. Treating the young person, who is testing for the first time the same as a person in their forties or fifties who has been tested dozens of times doesn't make sense. This important reform will allow AHF, the largest HIV tester in California, to do three times as many tests per hour as we do now. The unanimous approval of the legislature for this common sense approach to HIV testing is very encouraging."
The bill, known as the Sexually Transmitted Diseases and HIV/AIDS Counseling Reform Bill, unanimously cleared both chambers of the Legislature this week-clearing the California Assembly (64-0) earlier today after clearing the Senate in a 36 to 0 vote yesterday.
"This bill brings the requirements for HIV counseling in line with where we are today in our knowledge and understanding of HIV/AIDS and other STDs, and it will allow us to focus our counseling efforts where they are most needed-to those at high risk and those who may test positive," said Joey Terrill, Acting Director of Public Affairs for AIDS Healthcare Foundation, co-sponsor of the bill. "The California Legislature has recognized the importance of this prudent public health legislation with its unanimous passage in both chambers. When this bill is chaptered into law, it will allow the Department of Public Health and the State Office of AIDS far more flexibility in its counseling regulations to best serve and reflect the needs of communities throughout California."
AB 2899 codifies the changes that testing organizations need to conform their practices to current needs and to facilitate the swift introduction of newer counseling models by the Office of AIDS.
About AHF
AIDS Healthcare Foundation (AHF) is the nation's largest non-profit HIV/AIDS healthcare provider. AHF currently provides medical care and/or services to more than 80,000 individuals in 20 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at www.aidshealth.org
Contacts
AIDS Healthcare Foundation
Ged Kenslea, 323-860-5225
Mobile: 323-791-5523
gedk@aidshealth.org
or
Lori Yeghiayan, 323-860-5227
Mobile: 323-377-4312
lori.yeghiayan@aidshealth.org
Thursday, August 7, 2008
Families Informed About Insurance Coverage With Medical Reimbursement Resource
Company Educates Consumers of Medicare Part C Advantage Plan Enrollment Period Deadline - March 31, 2008
Houston, TX - March 12 -- Medical Reimbursement Resource (MRR) LLC, a leading patient advocacy company in Houston, advises the Medicare community of March 31st Medicare Part C enrollment deadline and helps educate consumers on the best health insurance choices for their situation.
MRR professionals explain that the Medicare program is a federal program that helps senior citizens and other qualifying individuals pay for health care. Divided into parts, A, B, C, and D, Part C is an alternative to Parts A and B. Under Part C, private health insurance companies can contract with the federal government to offer Medicare benefits through their own policies.
"Medicare Part C Advantage Plans are not for everyone. Generally the choice of providers is more limited than with traditional Medicare Parts A & B. Individuals with special health problems and working with physicians that are important to them are recommended to remain on Medicare Parts A and B," said MRR owner Jane Lehto.
"However, it's great to have another insurance option available for Medicare beneficiaries. This is where Medicare Part C comes in," Lehto added.
Lehto and her staff help clients choose the right insurance coverage and receive all benefits to which they are entitled under their particular policy. With over 40 plans from which to choose in Texas, it is an often difficult process through which to navigate for the unknowing consumer.
Lehto further explained that the type of candidates qualifying for the Medicare Part C, particularly the Medicare Part C Advantage Plus plan, would be those in fragile health and on fixed incomes. The relatively new plans include either HMO's or PPO's and come with modest premiums. A vast number of physicians and hospitals participate in the plans.
"And effective this past January is the option for those switching from Medicare Parts A and B to return to their plans for whatever reason during the enrollment period from November 15 through December 31, 2008," said Lehto.
MRR also assists patients and their families with problem health insurance claims and medical bills, benefit issues, along with insurance choices and a myriad of issues that the consumer faces in today's challenging and complex insurance world. To learn more about Medical Reimbursement Resource LLC, call 1-713-526-0955 or log onto www.mrrmedical.com today.
Press Contact: Philip O'Hara
Company Name: Medical Reimbursement Resource LLC
Texas Phone: 713-526-0955
Website: www.mrrmedical.com
Wednesday, August 6, 2008
Predicted Increase in Female Mesothelioma Victims
LegalView Informs Mesothelioma Blog Readers of a Predicted Increase in Female Mesothelioma Victims
LegalView updated readers to an alarming prediction by researchers who said the number of female mesothelioma victims may increase within the next few years. Researchers said that asbestos in hair dryers that were previously unregulated may be the cause.
Denver, CO - July 21, 2008 -- LegalView, the most comprehensive legal resource on the Web, reported on its mesothelioma information blog a potential increase of mesothelioma cancer victims within the next few years, particularly among women, according to researchers. In 1979, the U.S. Consumer Product Safety Commission (CPSC) released information regarding 26 companies and manufacturers of hand-held hair dryers that had been made with asbestos. While the 26 companies had voluntarily taken action to correct the asbestos-containing hair dryers, individuals who had used the tainted hair dryers may be at risk for developing mesothelioma and should consider contacting a mesothelioma lawyer for information on the development of a potential mesothelioma lawsuit.
Mesothelioma is a deadly form of lung cancer that is caused through the inhalation of asbestos fibers. While asbestos was largely used in the construction industry, commonly within insulation, it has also been used in other products including hair dryers. While the hair dryers were corrected and became asbestos-free nearly 30 years ago it is common for mesothelioma to remain dormant for years and even decades, which is why researchers are concerned with a new group of individuals becoming afflicted by mesothelioma and symptoms becoming prevalent now. Researchers are also particularly concerned for women because women allegedly use hair dryers more than men. To learn more about developing litigation, contact a mesothelioma law firm or mesothelioma attorney to better understand the potential for developing an asbestos-related lawsuit and receiving monetary compensation for the costly bills usually associated with a mesothelioma cancer diagnosis.
In addition to information on mesothelioma, LegalView also offers details on a plethora of other legal issues afflicting millions of Americans each year. For example, readers can learn about the latest fluoroquinolones black box warning labeling. Fluoroquinolones are a group of antibiotics that have become increasingly at risk for severe side effects. Of the fluoroquinolones group, the most commonly prescribed drugs are Levaquin and Cipro. Levaquin, also known as levofloxacin, is manufactured by Ortho-McNeil and treats bacterial infections, specifically treating infections such as skin infections, chronic bacterial prostates, urinary tract infections, pneumonia, bronchitis and acute pyelonephritis caused by Escherichia coli (E. coli). The drug, which was released in 1996, has been the center of numerous clinical trials and studies because of the possible Levaquin side effects, which can include the most serious - Achilles tendon rupture - as well as jaundice, seizures, hallucinations, abdominal tenderness and limb numbness.
Similar to Levaquin is Cipro (ciprofloxacin) from Bayer A.G., which was approved for market use in 2000 and is used to treat bacterial infections similar to those treated by Levaquin. The Cipro risks are the same as Levaquin, which is an increased risk of tendonitis. Additionally, Cipro has other side effects that may also be harmful to patients. Some of the side effects include seizure, difficulty breathing, depression, suicidal thoughts, blacking out and hallucinations.
LegalView also has information on other controversial prescription drugs including Avandia. Avandia is a type 2 diabetes drug that has recently been linked to severe risks among patients. The Avandia dangers may include an increased risk of heart failure as well as a higher risk of developing early onset osteoporosis. Patients who may have developed either of these side effects while taking Avandia should speak with an experienced pharmaceutical lawyer to better understand the potential for developing a potential Avandia lawsuit.
About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.
Sunday, July 27, 2008
Foundation Funds Follow-up Care in Revolutionary Cancer Vaccine Study
The Onyx & Breezy Foundation recently funded after-care for dogs engaged in a revolutionary research study to develop a cancer vaccine that may be given to both humans and animals when successful. The study is being conducted at The Matthew J. Ryan Veterinary Hospital, a small animal teaching hospital affiliated with the University of Pennsylvania in Philadelphia.
Tuxedo Park, NY and Philadelphia, PA - March 14 -- The Onyx & Breezy Foundation has announced a gift to The University of Pennsylvania School of Veterinary Medicine. The gift will cover the expense of follow-up care for 12 dogs that are currently enrolled in the School's cancer vaccine study.
"Thanks to this generous gift, more participants in our lymphoma cancer vaccine clinical trial will be able to return for follow-up care," said Dr. Karin Sorenmo, chief of oncology at the Matthew J. Ryan Veterinary Hospital. "This means that we can capture all the data that is needed for the study while pet owners are helped financially."
Prior gifts to The Matthew J. Ryan Veterinary Hospital from the Foundation have been a respirator for their ICU department and a mast cell tumor research study.
Dr. Sorenmo treated Breezy, who had mast cell tumors. "Thanks to Dr. Sorenmo, Breezy lived another 2 years, of quality life, after other vets gave her only 6 weeks to live," said Wanda Shefts. "We are glad that this project will help owners of dogs in remission from lymphoma and help advance Dr. Sorenmo's work on the cancer vaccine.
Dr. Sorenmo stated that she was encouraged by the results and she is hoping that this is just the beginning of more trials that can benefit dogs and ultimately help people. Thanks to this study, a number of the participating dogs are now cancer free. The researchers now estimate that they are within two years of testing the vaccine on humans. Without the dogs, they would be more than a decade away.
"We have a tremendous amount of respect for the work they do at the Hospital and we are glad to be able to fund another project for them", said Mark Shefts.
For more information about Penn Vet, please visit www.vet.upenn.edu; for more information about The Onyx and Breezy Foundation, please visit www.onyxandbreezy.org.
The Onyx and Breezy Foundation Background
The Foundation was created in 2004 and named after the trustees Mark & Wanda Shefts' two Labrador Retrievers. The Foundation lends financial support to organizations that benefit the welfare of animals.
The University Of Pennsylvania School Of Veterinary Medicine Background
Penn's School of Veterinary Medicine is one of the world's premier veterinary schools. Founded in 1884, the School was built on the concept of Many Species, One MedicineTM. The birthplace of veterinary specialties, the School serves a distinctly diverse array of animal patients, from pets to horses to farm animals.
Press Contact: Barbara Kauffman
Company Name: The Onyx & Breezy Foundation
Phone: 201-782-7400
Website: www.onyxandbreezy.org
Wednesday, July 9, 2008
Baxter Heparin Information on Additional Heparin Recall
LegalView updated its Baxter Heparin information portal to add information on the most recent recall of the blood-thinning drug. Heparin, which is used to control blood during surgical procedures, was recently discovered to have a Heparin-like contaminant that sickened many and caused at least 19 deaths.
Denver, CO - March 31, 2008 -- The Baxter Heparin practice area on LegalView's site, the source for everything legal on the Web, was recently expanded to explain details of an additional Heparin recall . Heparin has been linked to hundreds of allergic reactions among patients as well as having been connected with 19 deaths. B. Braun Medical Inc. issued the most recent recall of Heparin, which was supplied from Scientific Protein Laboratories - the same company that supplied Baxter Healthcare Corporation with the contaminated Baxter Heparin. According to the U.S. Food and Drug Administration (FDA) and B. Braun Medical Inc., no one was reportedly sickened off of the Heparin from B. Braun Medical but it did have a "heparin-like contaminant," which was enough for the company to recall the drug.
Heparin is blood-thinner injected into patients who are undergoing surgical procedures such as heart disease or kidney dialysis. It is a drug that has been imported to the United States since the 1930s and is derived from pig intestines. Many surgeons find that Heparin is an extremely important drug because it prevents blood clots from forming during surgery, which can result in death among patients. However, earlier this year, a rash of individuals who had been given Heparin during a surgical procedure had allergic reactions. Individuals who have been affected by the contaminated Heparin should consider contacting a Heparin lawyer to learn about developing a Heparin class action lawsuit for which compensation may be derived from manufacturers if the tainted drug.
The Baxter Heparin that was initially recalled had been tainted with a chemical known as over-sulfated chondroitin sulfate. Through an FDA investigation, it was discovered that a Chinese company that produces the drug was responsible for the tainted Heparin. Although an investigation continues to be ongoing as to whether the chemical was intentionally or accidentally introduced into a batch of the Heparin. According to news reports, using the over-sulfated chondroitin sulfate allows for a reduction in the production of production for Heparin.
For information on additionally recalled prescription drugs or to report an adverse reaction to a prescribed drug, visit LegalView's many unsafe drugs information portals. Here, readers will find information on recently recalled drugs as well as prescription drugs under investigation such as Chantix, Avandia and Trasylol Aprotinin.
Chantix is a smoking cessation drug from Pfizer that was first introduced to the market, with FDA approval, in mid-2006. However, in late-2007 the FDA began an investigation into nearly 400 reports of suicidal tendencies and behaviors among patients. Additionally, nearly 37 suicides have been associated with the Chantix side effects, which include psychotic episodes, depression, suicidal thoughts and erratic behavior.
Avandia is a prescription drug used to treat diabetes 2 among patients; however, the drug has been linked to several serious side effects including an increased risk of heart disease and a higher chance of early onset osteoporosis. Individuals who are taking Avandia are advised to locate an experienced pharmaceutical law firm to receive consultation on an Avandia lawsuit.
Trasylol, also known as its generic version Aprotinin, is similar to Heparin in that it is used during surgical procedures to control blood loss. A study was released in 2006 from the New England Journal of Medicine, which found that the use of Trasylol Aprotinin increased the chances of a patient developing heart disease, kidney disease, stroke and death. Patients who received or may have received Trasylol or it's generic version should use LegalView's information portal to find an Trasylol attorney.
About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.
Press Contact: Katie Kelley
Company Name: LegalView
Phone: 720-771-3246
Website: http://baxter-heparin.legalview.com
Subscribe to Posts [Atom]